Welcome to LookChem.com Sign In|Join Free
  • or
Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-iodo-, methyl ester is a chemical compound that is a derivative of phenylalanine, an essential amino acid. It is a methyl ester, meaning it is an organic compound with a carboxyl group that has been replaced by a methoxy group. The presence of an iodine atom in the compound's structure gives it additional chemical and pharmacological properties. This chemical may have potential applications in pharmaceutical research and development, particularly in the synthesis of new drug compounds. Its properties and potential uses make it a subject of interest in the field of medicinal chemistry.

796072-33-8

Post Buying Request

796072-33-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

796072-33-8 Usage

Uses

Used in Pharmaceutical Research and Development:
Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-iodo-, methyl ester is used as a chemical intermediate for the synthesis of new drug compounds. Its unique structure and properties make it a valuable component in the development of innovative pharmaceuticals.
Used in Medicinal Chemistry:
Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-iodo-, methyl ester is used as a research tool in medicinal chemistry to explore its potential applications and interactions with biological systems. Its chemical properties and the presence of an iodine atom make it an interesting candidate for further investigation and development in the field.

Check Digit Verification of cas no

The CAS Registry Mumber 796072-33-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,6,0,7 and 2 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 796072-33:
(8*7)+(7*9)+(6*6)+(5*0)+(4*7)+(3*2)+(2*3)+(1*3)=198
198 % 10 = 8
So 796072-33-8 is a valid CAS Registry Number.

796072-33-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name N-tert-butyloxycarbonyl-(L)4-iodophenylalanine methyl ester

1.2 Other means of identification

Product number -
Other names methyl N-Boc 4-iodophenylalanine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:796072-33-8 SDS

796072-33-8Relevant academic research and scientific papers

Simple and Efficient Generation of Aryl Radicals from Aryl Triflates: Synthesis of Aryl Boronates and Aryl Iodides at Room Temperature

Liu, Wenbo,Yang, Xiaobo,Gao, Yang,Li, Chao-Jun

supporting information, p. 8621 - 8627 (2017/07/06)

Despite the wide use of aryl radicals in organic synthesis, current methods to prepare them from aryl halides, carboxylic acids, boronic acids, and diazonium salts suffer from limitations. Aryl triflates, easily obtained from phenols, are promising aryl radical progenitors but remain elusive in this regard. Inspired by the single electron transfer process for aryl halides to access aryl radicals, we developed a simple and efficient protocol to convert aryl triflates to aryl radicals. Our success lies in exploiting sodium iodide as the soft electron donor assisted by light. This strategy enables the scalable synthesis of two types of important organic molecules, i.e., aryl boronates and aryl iodides, in good to high yields, with broad functional group compatibility in a transition-metal-free manner at room temperature. This protocol is anticipated to find potential applications in other aryl-radical-involved reactions by using aryl triflates as aryl radical precursors.

NOVEL AMINOPEPTIDASE INHIBITORS AND METHODS OF USE

-

Paragraph 0047, (2017/02/09)

An aminopeptidase inhibitor compound comprising a biaryl, hydroxamic acid based core of formula: wherein X is a 5 or 6-membered ring, and including pharmaceutically acceptable salts and solvates thereof.

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Drinkwater, Nyssa,Vinh, Natalie B.,Mistry, Shailesh N.,Bamert, Rebecca S.,Ruggeri, Chiara,Holleran, John P.,Loganathan, Sasdekumar,Paiardini, Alessandro,Charman, Susan A.,Powell, Andrew K.,Avery, Vicky M.,McGowan, Sheena,Scammells, Peter J.

, p. 43 - 64 (2016/01/30)

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.

SUBSTITUTED AMINO CARBOXYLIC ACIDS

-

Page/Page column 208-209, (2008/06/13)

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 796072-33-8